AVROBIO Management
Management criteria checks 3/4
AVROBIO's CEO is Erik Ostrowski, appointed in Jan 2019, has a tenure of 5.25 years. total yearly compensation is $1.59M, comprised of 31.7% salary and 68.3% bonuses, including company stock and options. directly owns 0.065% of the company’s shares, worth $35.14K. The average tenure of the management team and the board of directors is 2.5 years and 6 years respectively.
Key information
Erik Ostrowski
Chief executive officer
US$1.6m
Total compensation
CEO salary percentage | 31.7% |
CEO tenure | 5.3yrs |
CEO ownership | 0.07% |
Management average tenure | 2.5yrs |
Board average tenure | 6yrs |
Recent management updates
Recent updates
Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK
Oct 18Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status
Sep 20AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy
Jul 13Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Nov 13We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate
Aug 10AVROBIO: Fabrazyme's Full Approval Changes Things
May 05Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Mar 08AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise
Dec 25We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth
Nov 23AVROBIO readies $75M equity offering
Nov 19AVROBIO EPS misses by $0.19
Nov 05CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$2m | US$504k | US$12m |
Sep 30 2023 | n/a | n/a | -US$4m |
Jun 30 2023 | n/a | n/a | -US$5m |
Mar 31 2023 | n/a | n/a | -US$101m |
Dec 31 2022 | US$1m | US$460k | -US$106m |
Sep 30 2022 | n/a | n/a | -US$109m |
Jun 30 2022 | n/a | n/a | -US$119m |
Mar 31 2022 | n/a | n/a | -US$122m |
Dec 31 2021 | US$3m | US$439k | -US$119m |
Sep 30 2021 | n/a | n/a | -US$119m |
Jun 30 2021 | n/a | n/a | -US$123m |
Mar 31 2021 | n/a | n/a | -US$121m |
Dec 31 2020 | US$2m | US$424k | -US$120m |
Sep 30 2020 | n/a | n/a | -US$114m |
Jun 30 2020 | n/a | n/a | -US$95m |
Mar 31 2020 | n/a | n/a | -US$82m |
Dec 31 2019 | US$3m | US$412k | -US$73m |
Compensation vs Market: Erik's total compensation ($USD1.59M) is above average for companies of similar size in the US market ($USD677.87K).
Compensation vs Earnings: Erik's compensation has been consistent with company performance over the past year.
CEO
Erik Ostrowski (51 yo)
5.3yrs
Tenure
US$1,590,892
Compensation
Mr. Erik John Ostrowski, MBA, has been Chief Financial Officer and Treasurer at AVROBIO, Inc since January 2019 and served as its Principal Accounting Officer. He serves as President and Interim Chief Exec...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 5.3yrs | US$1.59m | 0.065% $ 35.1k | |
Chief Technology Officer | 2.3yrs | US$1.27m | 0.084% $ 45.2k | |
Chief Medical Officer | 2.5yrs | US$1.34m | 0.035% $ 19.1k | |
Scientific Founder | no data | no data | no data | |
Chief Legal Officer & Secretary | 5.3yrs | US$1.77m | 0.049% $ 26.4k | |
Vice President of Human Resource | 2.3yrs | no data | no data | |
Chief of Staff | no data | no data | no data |
2.5yrs
Average Tenure
47yo
Average Age
Experienced Management: AVRO's management team is considered experienced (2.5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Independent Director | 6.3yrs | US$63.97k | 0% $ 0 | |
Independent Non-Employee Director | 5.8yrs | US$72.97k | 0.0045% $ 2.4k | |
Independent Chairman of the Board | 8.2yrs | US$98.97k | 0% $ 0 | |
Independent Director | 5.3yrs | US$73.97k | 0.011% $ 5.8k | |
Director | 3.5yrs | US$61.47k | 0% $ 0 | |
Independent Director | 6yrs | US$76.97k | 0% $ 0 | |
Independent Director | 8.3yrs | US$72.97k | 0.56% $ 303.0k |
6.0yrs
Average Tenure
62yo
Average Age
Experienced Board: AVRO's board of directors are considered experienced (6 years average tenure).